HPAs

The Apex Molecular Advantage

• Expertise in the synthesis of HP small molecules offering upstream synthesis of cytotoxins for the Antibody Dug Conjugates (ADCs) market
• Combination of toxin-linker for development of novel payloads
• Capability and expertise to synthesise compounds on up to small gram scale to support pre clinical research and development
• All chemistry staff PhD level organic chemists
• Selection of Antibody Drug Conjugate (ADC) related products available from stock, both toxins (e.g. Duocarmycins, PBDs) and linkers (e.g. cleavable peptide derivatives such as Boc-Val-Ala-PAB-PNP)

• Clean room with isolator independently tested and operates at OEL < 1ng.m³ as an 8 hour time weighted average (TWA) allowing containment of most potent HPAPIs
• Separate wet chemistry lab dedicated to high potency synthesis
• Air handling system that operates under negative pressure cascade
• Detailed safety protocols, standard operating procedures and full risk assessments carried out
• Fully trained staff
• Analytical capabilities include 500 MHz NMR and LCMS

• Customer confidentiality and IP protection guaranteed
• Customers include technology developers for toxins, linkers, antibodies and Antibody Drug Conjugates (ADCs)
• Single point of contact and clear customer communication and project updates to ensure all information is shared to allow project decisions to be taken efficiently
• Bespoke solutions to our customers’ research project challenges through flexible project execution

Please complete the contact form to receive additional information or book a call from one of our technical experts.